Form 4: Ocular Therapeutix CDO Sells Shares for Tax Obligations

Ocular Therapeutix's Chief Development Officer, Peter Kaiser, sold 3,007 shares of common stock at a weighted average price of $12.02 to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Peter Kaiser, Chief Development Officer of Ocular Therapeutix, Inc. (OCUL), reported a sale of common stock.
• The transaction involved 3,007 shares of OCUL common stock.
• The shares were sold at a weighted average price of $12.02 per share, with prices ranging from $11.74 to $12.28.
• The sale was executed on November 24, 2025.
• This sale was not a discretionary trade but was made pursuant to a Rule 10b5-1 plan adopted on April 9, 2024.
• The purpose of the sale was to satisfy tax withholding obligations incurred from the vesting of restricted stock units on November 22, 2025.
• Following this transaction, Peter Kaiser beneficially owns 191,433 shares of Ocular Therapeutix common stock.

Sentiment

Score: 5

Explanation: The transaction is a non-discretionary sale to cover tax obligations from RSU vesting, which is a routine event and does not indicate a change in management's view of the company's prospects.

Positives

• The sale was non-discretionary, executed under a pre-arranged Rule 10b5-1 plan, indicating a planned transaction rather than a reaction to market conditions.
• The transaction was for tax withholding obligations related to the vesting of restricted stock units, which are a form of equity compensation for the officer.

Negatives

• A reduction in direct beneficial ownership of 3,007 shares by a key executive.

Future Outlook

NA

Management Comments

• Represents shares of common stock of Ocular Therapeutix, Inc. sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on November 22, 2025.
• The sales do not represent a discretionary trade by the reporting person.

Industry Context

This is a routine insider transaction for tax purposes, common across all industries for executives receiving equity compensation. It does not reflect specific industry trends for Ocular Therapeutix.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but for a non-discretionary reason, so minimal negative impact.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by a Chief Development Officer to cover tax obligations arising from RSU vesting. Such transactions are common and pre-scheduled under Rule 10b5-1 plans, indicating no change in the executive's fundamental outlook on the company or its prospects. Therefore, this specific filing does not provide new information that would warrant a change in investment recommendation.

Keywords

Ocular Therapeutix, OCUL, Peter Kaiser, Form 4, insider trading, stock sale, restricted stock units, RSU, tax withholding, 10b5-1 plan, Chief Development Officer